Long-term impact of eculizumab on quality of life and patient-reported symptoms of Japanese GBS patients at 52 weeks post disease onset: an observational survey

Long-term impact of eculizumab on quality of life and patient-reported symptoms of Japanese GBS patients at 52 weeks post disease onset: an observational survey - ECU-GBS-LTO study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000048078

Enrollment

Registered

2022-06-17

Start date

2022-07-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Guillain-Barre syndrome

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients with GBS enrolled in the parent ECU-GBS-301 trial who have completed the 4 times study drug treatment schedule in the parent trial and who have two measures of the PRO (one at baseline and at least one post-baseline) 2.Discontinuers of the parent ECU-GBS-301 trial meeting the inclusion/exclusion criteria maybe included 3.Patients who signed and dated the informed consent document indicating that they have been informed of all important aspects of the study

Exclusion criteria

Exclusion criteria: Patients who are unable to answer the study questionnaires and who do not have any next of kin or caregiver available to answer the study questionnaire on their behalf

Design outcomes

Primary

Measure	Time frame
Inflammatory Rasch-Built Overall Disability Scale (I-RODS) Short Form McGill Pain Questionnaire 2 (SF-MPQ-2) DASS: Depression Anxiety Stress Scale (DASS-21) EuroQoL- 5 Dimension 5 Level (EQ-5D-5L)	—

Countries

Japan

Contacts

Public ContactTakashi Sato

IQVIA Services Japan K.K. Real-World Evidence Services

takashi.sato3@iqvia.com03-6859-9500

Outcome results